Compound class:
Synthetic organic
Comment: The structure for civorebrutinib was obtained from proposed INN list 129 (August 2023), where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is claimed in patent WO2019091440A1 (SINOMAB Bioscience) [1]. Review of SINOMAB's online pipeline page suggests that civorebrutinib is likely their lead BTK inhibitor SN1011.
|
|
Immunopharmacology Comments |
A third generation BTK inhibitor proposed to treat autoimmune diseases. |